Evaluation of treatment options of central serous chorioretinopathy

Evaluation of comparative effect of intravitreal bevasizumab on visual acuity and central macular thickness in patient with central serous chorioretinopathy

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2017041533448N1

Enrollment

Registered

2017-05-24

Start date

2017-05-31

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Central Serous Chorioretinoathy. Central Serous Chorioretinopathy

Interventions

Intervention 1: Control group : without any intervention , just close abservation ( 15 patinets ). Intervention 2: Intervention group : 1.25 mg intravireal injection of bevasizumab , one time intravit

Diagnosis

Treatment - Drugs

Control group : without any intervention , just close abservation ( 15 patinets )

Intervention group : 1.25 mg intravireal injection of bevasizumab , one time intravitreal injection ( 15 patinets )

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion criteria: Patients with visual loss (2 lines Snellen chart or more) and in scan (the thickness of the central part of the macula greater than 250 microns) diagnosis of central serous chorioretinopathy they laid is. Exclusion criteria: Patient with visual loss with pathological retinal diseases other than Central serous retinopathy and diabetic retinopathy and hypertensive retinopathy and retinal dystrophies and patients who do not have the desire to enter the study.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Visual acuity. Timepoint: Before start the study and 2 months and 4 months after intervention. Method of measurement: Snellen acuity chart.	—

Secondary

Measure	Time frame
Central Maclar Thickness. Timepoint: Before start the study and 2 months and 4 months after intervention. Method of measurement: Optical Coherence Tomography.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Reza Shahraki

Vice chancellor for research, Zahedan University of Medical Sciences

m_Shahrakim@zaums.ac.ir+98 54 3329 5725

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026